Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
---|---|---|---|---|---|---|
Income Statement | ||||||
Total Revenue | 7.10B | 7.10B | 7.09B | 7.39B | 7.11B | 7.34B |
Gross Profit | 3.21B | 3.21B | 3.05B | 2.91B | 2.54B | 3.20B |
EBITDA | 1.45B | 1.17B | 736.00M | 577.00M | 928.00M | 1.20B |
Net Income | 810.00M | 810.00M | 280.00M | 149.00M | 462.00M | 710.00M |
Balance Sheet | ||||||
Total Assets | 5.56B | 5.56B | 5.75B | 5.95B | 6.16B | 6.33B |
Cash, Cash Equivalents and Short-Term Investments | 167.00M | 167.00M | 202.00M | 367.00M | 183.00M | 319.00M |
Total Debt | 2.88B | 2.88B | 2.90B | 2.92B | 3.10B | 3.17B |
Total Liabilities | 5.08B | 5.08B | 5.26B | 5.56B | 5.43B | 5.74B |
Stockholders Equity | 321.00M | 321.00M | 328.00M | 220.00M | 556.00M | 411.00M |
Cash Flow | ||||||
Free Cash Flow | 761.00M | 761.00M | 483.00M | 930.00M | 535.00M | 945.00M |
Operating Cash Flow | 981.00M | 981.00M | 695.00M | 1.16B | 786.00M | 1.28B |
Investing Cash Flow | -94.00M | -94.00M | -175.00M | -223.00M | -229.00M | -452.00M |
Financing Cash Flow | -924.00M | -924.00M | -655.00M | -753.00M | -689.00M | -1.39B |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
78 Outperform | $374.83B | 24.59 | 31.23% | 2.58% | 0.29% | 7.85% | |
71 Outperform | $23.34B | 45.19 | 12.07% | 1.22% | 1.13% | -34.78% | |
63 Neutral | $68.80B | 23.93 | 705.21% | 2.40% | 0.05% | 3.55% | |
63 Neutral | $20.52B | 14.80 | -2.68% | 3.09% | 1.95% | -4.76% | |
62 Neutral | $15.54B | 19.49 | 249.61% | 3.86% | 0.16% | 191.17% | |
60 Neutral | $43.09B | 17.90 | 196.26% | 3.85% | -6.89% | 7.52% | |
50 Neutral | $32.10B | 147.29 | -24.69% | 1.57% | -8.14% | -389.12% |
On July 31, 2025, Clorox reported its financial results for the fourth quarter and fiscal year 2025, highlighting a 4% increase in net sales to $2.0 billion, driven by ERP-related shipments, despite challenges such as unfavorable price mix and divestitures. The company achieved a significant 55% increase in diluted EPS and a 58% rise in adjusted EPS, attributed to higher volumes and cost savings, although it faced market volatility and shifting consumer behaviors. Clorox’s strategic advancements include the implementation of a new ERP system in the U.S. to support long-term growth, with expectations of reversing ERP shipment benefits in fiscal year 2026.